Amgen, Inc.

Amgen, Inc. logo
🇺🇸United States
Ownership
Public
Established
1980-01-01
Employees
26.7K
Market Cap
$175.6B
Website
http://www.amgen.com
Clinical Trials
Related News

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Phase 2
Completed
Conditions
Breast Cancer
Fever
Neutropenia
First Posted Date
2005-06-23
Last Posted Date
2008-08-01
Lead Sponsor
Amgen
Registration Number
NCT00115414

Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

Phase 4
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2005-06-22
Last Posted Date
2013-05-30
Lead Sponsor
Amgen
Target Recruit Count
200
Registration Number
NCT00115219

Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Completed
Conditions
Normal PBPC Donors
Interventions
Drug: filgrastim
First Posted Date
2005-06-22
Last Posted Date
2013-05-13
Lead Sponsor
Amgen
Target Recruit Count
309
Registration Number
NCT00115128

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Phase 4
Completed
Conditions
Non-Small Cell Lung Cancer
First Posted Date
2005-06-22
Last Posted Date
2009-04-06
Lead Sponsor
Amgen
Registration Number
NCT00115206

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Non-Hodgkin's Lymphoma
Interventions
Drug: pegfilgrastim
First Posted Date
2005-06-22
Last Posted Date
2013-08-29
Lead Sponsor
Amgen
Target Recruit Count
77
Registration Number
NCT00115193

Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

Phase 2
Completed
Conditions
Myeloid Leukemia
Interventions
Drug: filgrastim
Drug: pegfilgrastim
First Posted Date
2005-06-20
Last Posted Date
2008-10-31
Lead Sponsor
Amgen
Target Recruit Count
84
Registration Number
NCT00114764

Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)

Phase 2
Completed
Conditions
End Stage Renal Disease
First Posted Date
2005-06-13
Last Posted Date
2013-05-13
Lead Sponsor
Amgen
Target Recruit Count
360
Registration Number
NCT00113945

Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
Interventions
Other: PI Discretion
First Posted Date
2005-06-13
Last Posted Date
2009-02-13
Lead Sponsor
Amgen
Target Recruit Count
21
Registration Number
NCT00113789

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Phase 4
Completed
Conditions
Chronic Renal Failure
Anemia
First Posted Date
2005-05-30
Last Posted Date
2008-08-08
Lead Sponsor
Amgen
Target Recruit Count
400
Registration Number
NCT00111995

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Phase 2
Completed
Conditions
Colorectal Cancer
Carcinoma
First Posted Date
2005-05-26
Last Posted Date
2013-05-14
Lead Sponsor
Amgen
Target Recruit Count
150
Registration Number
NCT00111774
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy